CAR-T cell therapy: current limitations and potential strategies

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Chimeric antigen receptor (CAR)-T cell therapy is a groundbreaking cancer treatment.
• While effective for some B cell leukemias/lymphomas, its efficacy is limited in solid tumors and other hematological malignancies.
• Key challenges include toxicity, limited anti-tumor activity, antigen escape, and poor tumor infiltration.

Purpose of the Study:

• To review recent innovations in CAR-T cell engineering.
• To discuss strategies for overcoming limitations of CAR-T cell therapy.
• To improve clinical efficacy in both hematological malignancies and solid tumors.

Main Methods:

• Review of current literature on CAR-T cell therapy.
• Analysis of engineering strategies to enhance CAR-T cell function.
• Discussion of approaches to mitigate CAR-T cell-related toxicities.

Main Results:

• CAR-T cell therapy has achieved significant responses in certain blood cancers.
• Numerous barriers hinder CAR-T cell effectiveness in solid tumors and broader hematological malignancies.
• Host- and tumor-microenvironment interactions significantly impact CAR-T cell performance.

Conclusions:

• Innovative engineering strategies are essential to enhance CAR-T cell anti-tumor activity and reduce toxicity.
• Overcoming current limitations is critical for expanding the therapeutic applications of CAR-T cell therapy.
• Further research is needed to optimize CAR-T cell treatments for diverse cancer types.